Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients
- Conditions
- HIV Infection
- Interventions
- Biological: one injection of vCP1452 at W0, W4, W8 and W20Biological: one injection of vCP1452 at W4, W8 and W20Biological: one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20
- Registration Number
- NCT00219362
- Lead Sponsor
- Objectif Recherche Vaccins SIDA
- Brief Summary
Prior pilot studies have shown that four monthly injections of ALVAC-HIV (vCP1433) are immunogenic in 60% HIV-infected patients with a boosting effect obtained after 1 or 2 injections followed by a plateau or a decrease of these responses prior to interrupting therapy. The goal of the present study is to look for an improved vaccination schedule in terms of strength and duration of the HIV-specific immunity induced by the HIV-recombinant canary pox vector ALVAC-HIV (vCP1452) by testing a strategy of immunization involving a first series of two versus three monthly injections followed by a boost three months later.
- Detailed Description
Manon 02 is a phase II, multicentre, randomized, placebo-controlled study with 3 arms comprising 2 steps:
Step I : Immunization phase from W0 to W24, on HAART
The immunization will be administered by intramuscular injection :
Arm A: one injection of vCP1452 at W0, W4, W8 and W20 + HAART, for a total of 4 injections Arm B: one injection of vCP1452 at W4, W8 and W20 + HAART, for a total of 3 injections Arm C: one injection of placebo at W0, W4, W8 and W20 + HAART, for a total of 4 injections or at W4, W8 and W20 + HAART, for a total of 3 injections
Step II: Post immunization phase from W24 to W48, off HAART
Discontinuation of antiretroviral therapy (ARV) from W24 to W48 :
The ARV treatment interruption will be proposed at W24, 4 weeks after the last immunization, to patient who had completed their immunization phase and have CD4 cell counts \> 350 cells/mm3 and HIV plasma RNA \< 400 cp/ml.
In order to be able to evaluate the capacity of the immune response to reduce the viral replication, a period of 16 weeks of interruption is recommended from W24 to W40.
Resumption of antiretroviral therapy :
From W24 to W40 : During this 16 weeks period, in case of a decline of CD4 cell counts below 250 cells/mm3 or of a loss of CD4 greater than 50% of the baseline value, HAART will be restarted.
From W40 to W48 : HAART should be reintroduced if HIV-1 RNA levels \> 50 000 cp/ml on 2 consecutive measurements at two weeks interval even if the CD4 counts are above 250 cells/mm3.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 65
- Documented HIV infection
- under potent antiretroviral therapy for more than 6 months
- with entry CD4+ counts > 350 cells/mm3 for at least 1 year
- plasma HIV RNA < 400 cp/ml for at least the last 6 months
- Contraception needed for women
- Antiretroviral therapy started with CD4 cell count > 400/mm3
- Patients treated at time of primary HIV infection
- Patient with past AIDS defining event
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ALVAC-HIV 4 injections one injection of vCP1452 at W0, W4, W8 and W20 Arm A: injection of ALVAC-HIV(vCP1452) for a total of 4 injections (W0, W4, W8, W20) ALVAC-HIV 3 injections one injection of vCP1452 at W4, W8 and W20 Arm B: injection of ALVAC-HIV(vCP1452) for a total of injections (W4, W8, W20) Placebo - 4 injections one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20 Arm C1: injection of placebo for a total of 4 injections (W0, W4, W8, W20) Placebo - 3 injections one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20 Arm C2: injection of placebo for a total of 3 injections (W4, W8, W20)
- Primary Outcome Measures
Name Time Method Change from baseline of the frequency of HIV-specific PBMC (CD4/CD8) at W24 (4 weeks after the last immunization)
- Secondary Outcome Measures
Name Time Method - Percentage of responders as defined by an increase of at least 0.7 log10 from baseline of the frequencies of HIV-specific PBMC and/or CD4 and/or CD8 T cells four weeks after the last immunization(W24) as measured by ELISpot IFNγ - Change from baseline of the frequency of HIV-specific PBMC and/or CD4 and/or CD8 T cells at week 4, 6, 8, 12, 20 and 24 in the study arms as measured by ELISpot IFNγ - Evaluation of the magnitude of CD4 and CD8 T cell response at W4, W6, W8, W12, W20, W24 in the study arms - Evaluation of the immune responses, HIV-specific PBMC and/or CD4 and/or CD8 T cells at W48 - Percentage of patients who generate a primary immune response against the artificial pol/nef sequences present in the vaccine but not in the HIV strain - Evaluation of the immune responses directed to vCP1452 in the study arms at all study point during the immunization phase - Percentage of patients who do not reach the restart therapy criteria from W24 to W48 - Percentage of patients who remain off therapy at W48 - Evaluation of the safety and tolerability of the vCP1452
Trial Locations
- Locations (5)
Northwestern University Medical School
🇺🇸Chicago, Illinois, United States
Fundacio Irsi Caixa Retrovirology Laboratory, Hospital Universitari Germans
🇪🇸Badalona, Spain
Servicios de Infecciosos, Hospital y clinic Provincial
🇪🇸Barcelona, Spain
Klinikum der Johann Nolfgang Goethe Universitat Zentrum des Innerin Medizin
🇩🇪Frankfurt Am Main, Germany
Service des maladies infectieuses et tropicales, Hopital Pitié-Salpétrière, Pavillon Laveran
🇫🇷Paris, France